Atezolizumab and bevacizumab combination gets EC nod to treat liver cancer: RocheNovember 4, 2020
Roche gets the European Commission (EC) nod for combination therapy of atezolizumab (Tecentriq) and bevacizumab (Avastin) to treat adult patients with advanced or unresectable hepatocellular carcinoma (HCC).
The combination therapy becomes the first and only cancer immunotherapy regimen approved in Europe for the treatment of HCC, the most common form of liver cancer.
The atezolizumab and bevacizumab regimen can potentially improve the ability of the immune system to fight a broad range of cancers. The monoclonal antibody atezolizumab can attach with a protein called PD-L1, expressed on tumour cells and tumour-infiltrating immune cells. Bevacizumab is a biologic antibody that binds vascular endothelial growth factor (VEGF) protein that plays an important role in tumour angiogenesis.
The approval is based on results from the phase III IMbrave150 study, which demonstrated that atezolizumab (Tecentriq) in combination with bevacizumab (Avastin) reduced the risk of death (overall survival (OS)) by 42% compared with sorafenib. It also reduced the risk of disease worsening or death by 41% versus sorafenib.
In September, Roche received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for the combination treatment. The combination now holds approval in 59 countries for patients with unresectable HCC.